"Ezetimibe" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.
| Descriptor ID |
D000069438
|
| MeSH Number(s) |
D03.383.082.301.550
|
| Concept/Terms |
Ezetimibe- Ezetimibe
- (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
- Ezetimib
SCH 58235- SCH 58235
- 58235, SCH
- SCH-58235
- SCH58235
|
Below are MeSH descriptors whose meaning is more general than "Ezetimibe".
Below are MeSH descriptors whose meaning is more specific than "Ezetimibe".
This graph shows the total number of publications written about "Ezetimibe" by people in this website by year, and whether "Ezetimibe" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 5 | 5 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 5 | 3 | 8 |
| 2017 | 4 | 2 | 6 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 5 | 7 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ezetimibe" by people in Profiles.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
-
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD? J Fam Pract. 2023 06; 72(5):227-229.
-
Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes. 2022 12; 15(12):e008861.
-
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022 Dec; 45(12):1303-1310.
-
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
-
Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 08 02; 11(15):e024531.
-
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022 May-Jun; 16(3):286-297.
-
Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 02 09; 28(18):2001-2009.
-
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
-
Treatment Inertia in Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021 07 20; 10(14):e020126.